In this large community-based study, subjects with higher hs-CRP levels showed a mild increase in the prevalence of asymptomatic ICAS, independent of traditional vascular risk factors. hs-CRP is an independent predictor of asymptomatic ICAS and intracranial atherosclerotic burden.

No abstract

No abstract

No abstract

ABSTRACT. We evaluated the clinical efficacy of tailoring tacrolimus dosage to cytochrome P450 (CYP) 3A5 genotype in liver transplant patients. One hundred patients who received tacrolimus-based therapy were included in the retrospective study in which the relationship between the tacrolimus blood trough concentration/dosage ratio and the CYP3A5 genotype of both donors and recipients was determined. Subsequently, 106 patients were continuously enrolled in a prospective study and followedup for 6 months; the relationship between tacrolimus dosage and CYP3A5 genotype was also determined. Rates of acute rejection, hepatotoxicity, renal toxicity, neurotoxicity, hypertension, and hyperglycemia were compared between the groups. During the 6 months following liver transplantation, the mean tacrolimus concentration/dosage ratio among patients who did not have the CYP3A5*1 genotype and who received a transplant from a L. Wang et al. 3192©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (2): 3191-3199 (2015) donor with the same genotype (24/100, 24% of patients) was higher than that among patients who did have the CYP3A5*1 genotype and/or had a donor with the same genotype (76/100, 76% of patients). In the second part of the study, the tacrolimus dosage was tailored to CYP3A5 genotype and 24 patients (22.64%) received a lower dose. There was an obvious decrease in acute rejection, hepatotoxicity, renal toxicity, neurotoxicity, hypertension, hyperglycemia, and Pneumocystis carinii infection among the latter group. A lower tacrolimus dose was suitable for about 25% of the liver transplant patients, as these patients did not have the CYP3A5*1 genotype and received a transplant from a donor with the same genotype. Tailoring the tacrolimus dosage according to the CYP3A5 genotype could reduce rejection and adverse effects.

ABSTRACT. The Beijing Heart Lung and Blood Vessel Medical Center has participated in the World Health Organisation MONICA project since 1981. Our study, named Sino‐MONICA‐Beijing, has been carried out in Beijing and covers a population approximately of 700,000. After a 2‐year pilot study, the project started formally January 1, 1984. This paper presents the organization and methodology of the study, with emphasis on the monitoring system and on how events were found. The main results of the cardiovascular disease (CVD) event monitoring are as follows: average annual mortality from all causes, for the 3‐year period of 1984–86 was 319/100,000 for men and 238/100,000 for women aged 25–64; from CVD 119/100,000 for men and 101/100,000 for women; from ischemic heart disease 29/100,000 for men and 14/100,000 for women; and from cerebrovascular disease 59/100,000 for men and 52/100,000 for women. Preliminary experience has shown that Sino‐MONICA‐Beijing is a well‐standardized project of long‐term surveillance of CVD in the communities of Beijing.

Introduction: Endovascular treatment (EVT) performed in the early time window has been shown to decrease the incidence of malignant middle cerebral artery infarction (MMI). However, the incidence of MMI in patients undergoing EVT during the late time window is unclear. This study aimed to investigate the prevalence of MMI in patients undergoing late EVT and compare it with that in patients undergoing early EVT. Patients and methods: We retrospectively analyzed consecutive patients with anterior large vessel occlusion stroke who underwent EVT at Xuanwu Hospital between January 2013 and June 2021. Eligible patients were divided into early EVT (within 6 h) and late EVT (6–24 h) groups according to the time from their stroke onset to puncture and compared. The occurrence of MMI post-EVT was the primary outcome. Results: A total of 605 patients were recruited, of whom 300 (50.4%) underwent EVT within 6 h and 305 (49.6%) underwent EVT within 6–24 h. A total of 119 patients (19.7%) developed MMI. 68 patients (22.7%) in the early EVT group and 51 patients (16.7 %) in the late EVT group developed MMI (P = 0.066). After adjusting for covariate variables, late EVT was independently associated with a lower incidence of MMI (odds ratio, 0.404; 95% confidence interval, 0.242–0.675; P = 0.001). Conclusion: MMI is not an uncommon phenomenon in the modern thrombectomy era. Compared with the early time window, patients selected by stricter radiological criteria to undergo EVT in the late time window are independently associated with a lower incidence of MMI.

No abstract